Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.
PanCAN’s Scientific & Medical Advisory Board (SMAB) welcomes new leadership and members, representing the foremost expertise in the field of pancreatic cancer from institutions across the US.
Nonprofit’s Scientific and Medical Advisory Board Represented by Foremost Leaders in Pancreatic Cancer Field LOS ANGELES, Calif. – (July 18, [.] READ MORE
/PRNewswire/ The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of.
As more is understood about the biology of PDAC tumors, targeting common KRAS variants in these tumors following exhaustion of all curative intent surgery, chemotherapy, and radiation ushers in a novel postadjuvant setting for investigators.